Hospital reimbursement for adult patients with severe sepsis treated with drotrecogin alfa (activated)

Hospital Pharmacy

Volumn 40, Issue 2, 2005, Pages 146-153

  Smith, Brian S ^a   Schroeder, Walter S ^b   Tataronis, Gary R ^c  

^a UMASS MEMORIAL MEDICAL CENTER   (United States)

^b BOSTON MEDICAL CENTER   (United States)

^c MA Coll of Pharm and Hlth Sci   (United States)

Author keywords

Drotrecogin alfa (activated); Reimbursement; Severe sepsis

Indexed keywords

DROTRECOGIN;

ARTIFICIAL VENTILATION; COMPENSATION; CONTROLLED STUDY; DEMOGRAPHY; DISEASE SEVERITY; EVALUATION; HEALTH CARE PLANNING; HEALTH PRACTITIONER; HOSPITAL COST; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MEDICAL INFORMATION SYSTEM; REIMBURSEMENT; REVIEW; SEPSIS; UNIVERSITY HOSPITAL;

EID: 13444278825     PISSN: 00185787     EISSN: None     Source Type: Journal    
DOI: 10.1177/001857870504000206     Document Type: Review

References (11)

1. Hoffman JM, Shah ND, Vermuelen CL, Hunkler RJ, Hontz KM. Projecting future drug expenditures - 2004. Am J Health-Syst Pharm. 2004;61(2):145-158.
2. Weber RJ, Kane SL, Oriolo VA, Saul M, Skledar SJ, Dasta JF. Impact of intensive care unit (ICU) drug use on hospital costs: a descriptive analysis, with recommendations for optimizing ICU pharmacotherapy. Crit Care Med. 2003;31(suppl.):S17-S24.
3. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;29(7):1303-1310.
4. Xigris (drotrecogin alfa (activated)) [package insert]. Indianapolis, IN: Eli Lilly and Company; 2003.
5. Angus DC, Linde-Zwirble WT, Clermont G, et al. Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis. Crit Care Med. 2003;31(1):1-11.
6. Manns BJ, Lee H, Doig CJ, Johnson D, Donaldson C. An economic evaluation of activated protein C treatment for severe sepsis. N Engl J Med. 2002;347(13):993-1000.
7. Teres D, Rapport J, Lemeshow S, Kim S, Akhras K. Effects of severity of illness on resource use by survivors and nonsurvivors of severe sepsis at intensive care unit admission. Crit Care Med. 2002;30(11):2413-2419.
8. Centers for Medicare and Medicaid Services. Proposed add-on payments for new services and technologies. Fed Regist. 2002;67(90):31427-21430.
9. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344(10):699-709.
10. Dellinger RP, Carlet JM, Masur H, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med. 2004;32(3):858-873.
11. Centers for Medicare and Medicaid Services. Medicare Program; changes to the hospital inpatient prospective payment systems and fiscal year 2005 rates; final rule. Fed Regist. 2004;69:48915-49268.